Selected research
Market Structure
Global Polypeptide Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Polypeptide Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Polypeptide Drug include Takeda, Sanofi, Novartis, Roche, Lilly, Ferring Pharmaceuticals, AstraZeneca, SciClone Pharmaceuticals and Merck Serono, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Polypeptide Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Polypeptide Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Polypeptide Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Polypeptide Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Polypeptide Drug Segment by Company
Takeda
Sanofi
Novartis
Roche
Lilly
Ferring Pharmaceuticals
AstraZeneca
SciClone Pharmaceuticals
Merck Serono
Ipsen PHarma Biotech
Asahi Kasei
Polypeptide Drug Segment by Type
Injection
Oral Administration
Transdermal Administration
Lung Administration
Nasal Administration
Polypeptide Drug Segment by Application
Tumor Drug
Digestive System Drugs (Gastrointestinal Type)
Immunity Regulating Medicine (Allergy Infection and Immune)
Urinary System Drug
Bone and Connective Tissue Types (Thyroid hormones Drug)
Gynecologic or Obstetric Drug
Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Polypeptide Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polypeptide Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Polypeptide Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polypeptide Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Polypeptide Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Polypeptide Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Polypeptide Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Polypeptide Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral Administration
- Transdermal Administration
- Lung Administration
- Nasal Administration
Applications
- Tumor Drug
- Digestive System Drugs (Gastrointestinal Type)
- Immunity Regulating Medicine (Allergy Infection and Immune)
- Urinary System Drug
- Bone and Connective Tissue Types (Thyroid hormones Drug)
- Gynecologic or Obstetric Drug
- Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Companies covered
- Takeda
- Sanofi
- Novartis
- Roche
- Lilly
- Ferring Pharmaceuticals
- AstraZeneca
- SciClone Pharmaceuticals
- Merck Serono
- Ipsen PHarma Biotech
- Asahi Kasei
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Polypeptide Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Polypeptide Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Polypeptide Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Polypeptide Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Polypeptide Drug Market Dynamics
- 2.1 Polypeptide Drug Industry Trends
- 2.2 Polypeptide Drug Industry Drivers
- 2.3 Polypeptide Drug Industry Opportunities and Challenges
- 2.4 Polypeptide Drug Industry Restraints
3 Polypeptide Drug Market by Manufacturers
- 3.1 Global Polypeptide Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Polypeptide Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Polypeptide Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Polypeptide Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Polypeptide Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Polypeptide Drug Manufacturers, Product Type & Application
- 3.7 Global Polypeptide Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Polypeptide Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Polypeptide Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Polypeptide Drug Tier 1, Tier 2, and Tier 3
4 Polypeptide Drug Market by Type
- 4.1 Polypeptide Drug Type Introduction
- 4.1.1 Injection
- 4.1.2 Oral Administration
- 4.1.3 Transdermal Administration
- 4.1.4 Lung Administration
- 4.1.5 Nasal Administration
- 4.2 Global Polypeptide Drug Sales by Type
- 4.2.1 Global Polypeptide Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Polypeptide Drug Sales by Type (2021-2032)
- 4.2.3 Global Polypeptide Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Polypeptide Drug Revenue by Type
- 4.3.1 Global Polypeptide Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Polypeptide Drug Revenue by Type (2021-2032)
- 4.3.3 Global Polypeptide Drug Revenue Market Share by Type (2021-2032)
5 Polypeptide Drug Market by Application
- 5.1 Polypeptide Drug Application Introduction
- 5.1.1 Tumor Drug
- 5.1.2 Digestive System Drugs (Gastrointestinal Type)
- 5.1.3 Immunity Regulating Medicine (Allergy Infection and Immune)
- 5.1.4 Urinary System Drug
- 5.1.5 Bone and Connective Tissue Types (Thyroid hormones Drug)
- 5.1.6 Gynecologic or Obstetric Drug
- 5.1.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
- 5.2 Global Polypeptide Drug Sales by Application
- 5.2.1 Global Polypeptide Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Polypeptide Drug Sales by Application (2021-2032)
- 5.2.3 Global Polypeptide Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Polypeptide Drug Revenue by Application
- 5.3.1 Global Polypeptide Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Polypeptide Drug Revenue by Application (2021-2032)
- 5.3.3 Global Polypeptide Drug Revenue Market Share by Application (2021-2032)
6 Global Polypeptide Drug Sales by Region
- 6.1 Global Polypeptide Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Polypeptide Drug Sales by Region (2021-2032)
- 6.2.1 Global Polypeptide Drug Sales by Region (2021-2026)
- 6.2.2 Global Polypeptide Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Polypeptide Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Polypeptide Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Polypeptide Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Polypeptide Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Polypeptide Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Polypeptide Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Polypeptide Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Polypeptide Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Polypeptide Drug Revenue by Region
- 7.1 Global Polypeptide Drug Revenue by Region
- 7.1.1 Global Polypeptide Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Polypeptide Drug Revenue by Region (2021-2026)
- 7.1.3 Global Polypeptide Drug Revenue by Region (2027-2032)
- 7.1.4 Global Polypeptide Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Polypeptide Drug Revenue (2021-2032)
- 7.2.2 North America Polypeptide Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Polypeptide Drug Revenue (2021-2032)
- 7.3.2 Europe Polypeptide Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Polypeptide Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Polypeptide Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Polypeptide Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Polypeptide Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Polypeptide Drug Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Polypeptide Drug Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Polypeptide Drug Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Roche
- 8.4.1 Roche Company Information
- 8.4.2 Roche Business Overview
- 8.4.3 Roche Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Roche Polypeptide Drug Product Portfolio
- 8.4.5 Roche Recent Developments
- 8.5 Lilly
- 8.5.1 Lilly Company Information
- 8.5.2 Lilly Business Overview
- 8.5.3 Lilly Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lilly Polypeptide Drug Product Portfolio
- 8.5.5 Lilly Recent Developments
- 8.6 Ferring Pharmaceuticals
- 8.6.1 Ferring Pharmaceuticals Company Information
- 8.6.2 Ferring Pharmaceuticals Business Overview
- 8.6.3 Ferring Pharmaceuticals Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Ferring Pharmaceuticals Polypeptide Drug Product Portfolio
- 8.6.5 Ferring Pharmaceuticals Recent Developments
- 8.7 AstraZeneca
- 8.7.1 AstraZeneca Company Information
- 8.7.2 AstraZeneca Business Overview
- 8.7.3 AstraZeneca Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 AstraZeneca Polypeptide Drug Product Portfolio
- 8.7.5 AstraZeneca Recent Developments
- 8.8 SciClone Pharmaceuticals
- 8.8.1 SciClone Pharmaceuticals Company Information
- 8.8.2 SciClone Pharmaceuticals Business Overview
- 8.8.3 SciClone Pharmaceuticals Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 SciClone Pharmaceuticals Polypeptide Drug Product Portfolio
- 8.8.5 SciClone Pharmaceuticals Recent Developments
- 8.9 Merck Serono
- 8.9.1 Merck Serono Company Information
- 8.9.2 Merck Serono Business Overview
- 8.9.3 Merck Serono Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Merck Serono Polypeptide Drug Product Portfolio
- 8.9.5 Merck Serono Recent Developments
- 8.10 Ipsen PHarma Biotech
- 8.10.1 Ipsen PHarma Biotech Company Information
- 8.10.2 Ipsen PHarma Biotech Business Overview
- 8.10.3 Ipsen PHarma Biotech Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Ipsen PHarma Biotech Polypeptide Drug Product Portfolio
- 8.10.5 Ipsen PHarma Biotech Recent Developments
- 8.11 Asahi Kasei
- 8.11.1 Asahi Kasei Company Information
- 8.11.2 Asahi Kasei Business Overview
- 8.11.3 Asahi Kasei Polypeptide Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Asahi Kasei Polypeptide Drug Product Portfolio
- 8.11.5 Asahi Kasei Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Polypeptide Drug Value Chain Analysis
- 9.1.1 Polypeptide Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Polypeptide Drug Production Mode & Process
- 9.2 Polypeptide Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Polypeptide Drug Distributors
- 9.2.3 Polypeptide Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst